Colchicine versus placebo in Behçet’s disease: randomized, double-blind, controlled crossover trial

Mizushima Y, Matsumura N, Shimizu T, Fukushima B, Mimura Y, Saito K, et al. Colchicine in Behçet’s disease. Lancet. 1977;2:1037.

Haim S, Friedman-Birnbaum R. Colchicine in Behçet’s disease. Harefuah. 1977;93:399–400.

Hazen PG, Michel B. Management of necrotizing vasculitis with colchicine. Improvement in patients with cutaneous lesions and Behçet’s syndrome. Arch Dermatol. 1979;115:1303–6.

Raynor A, Askari AD. Behçet’s disease and treatment with colchicine. J Am Acad Dermatol. 1980;2:396–400.

Miyachi Y, Tanigushi S, Ozaki M, Horio T. Colchicine in the treatment of the cutaneous manifestations of Behçet’s disease. Br J Dermatol. 1981;104:67–9.

Moreno Moraga J, Estrada Saiz RV, Chantres Antoraz MT, Rivas Flores J, Gilsanz Garcia V. Therapeutic values of colchicine in Behçet’s disease. Med Clin (Barc). 1981;77:18–20.

Harper RM, Allen BS. Use of colchicine in the treatment of Behçet’s disease. Int J Dermatol. 1982;21:551–4.

Sander HM, Randle HW. Use of colchicine in Behçet’s syndrome. Cutis. 1986;37:344–8.

Aktulga E, Altac M, Muftuoglu Y, Pazarli H, Tuzun Y, Yalcin B, et al. A double blind study of colchicine in Behçet’s disease. Haematologica. 1980;65:399–402.

Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, Hamuryudan V, Omer Uysal, et al. A double-blind trial of colchicine in Behçet’s syndrome. Arthritis Rheum. 2001;44:2686–92.

Fontes V, Machet L, Huttenberger B, Lorette G, Vaillant L. Recurrent aphthous stomatitis: treatment with colchicine. An open trial of 54 cases. Ann Dermatol Venereol. 2002;129:1365–9.

Vidaller Palacin A, Robert Olalla J, Sanuy Jimenez B, Rufi Rigau G, Folch Civit J, Charte Gonzales A. Behçet’s disease therapy review. Ann Med Int. 2002;19:594–8.

Wechsler B. Colchicine and Behçet’s disease: an efficacious treatment finally recognized. Rev Med Int. 2002;23:355–6.

Lange U, Schumann C, Schmidt KL. Current aspects of colchicine therapy—classical indications and new therapeutic uses. Eur J Med Res. 2001;20:150–60.

Davatchi F, Jamshidi AR, Tehrani-Banihashemi A, Gholami J, Forouzanfar MH, Moradi M, et al. Prevalence of Behçet’s disease in Iran: a WHO-ILAR COPCORD Stage 1 study. APLAR J Rheumatol. 2007;10:239–43.

Davatchi F, Akbarian M, Shahram F, Tebbi ME, Chams C, Shams H. Iran Behçet’s disease dynamic activity measure. Abstracts of the XIIth European Congress of Rheumatology. Hungarian Rheumatol 1991;32(Suppl):FP10–100.

Jamshidi A, Shahram F, Akbarian M, Gharibdoost F, Nadji A, Chams C, et al. The accuracy of IBDDAM (Iran Behçet’s disease dynamic activity measure) in the treatment evaluation of Behçet’s disease. APLAR J Rheumatol. 2001;4:161–3.

Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ. Behçet’s disease evaluation of a new instrument to measure clinical activity. Rheumatology. 1999;38:728–33.

Lawton G, Bhakta BB, Chamberlain MA, Tennant A. The Behçet’s disease activity index. Rheumatology 2004;43:73–8.

Shahram F, Khabbazi A, Nadji A, Ziaie N, Tehrani Banihashemi A, Davatchi F. Comparison of the existing disease activity indices in the follow up of patients with Behçet’s disease. Mod Rheumatol 2009;19 (in press).